India’s Ministry of Health and Family Welfare has proposed requiring central permission before manufacturers can apply for state licenses to make antimicrobial drugs, citing concerns about regulatory scrutiny and product safety.
The draft, identified as G.S.R. 983(E) and dated Nov. 6, 2026, would add “antimicrobials” to the definition of a “New Drug” under the New Drugs and Clinical Trials Rules, 2019. The proposed change would require manufacturers to obtain approval from the Central Licensing Authority before seeking a manufacturing license from the relevant State Licensing Authority. The ministry announced the proposal, and the draft Gazette notification sets out the amendment.
The ministry said its concern is that some antimicrobial licenses may have been granted without sufficient regulatory review. It pointed to assessments of how a drug is absorbed and performs in the body, as well as studies of how stable it remains over time, saying missing assessments could affect quality, safety and efficacy.
The ministry also said products that do not work as intended or fall below standards can add to antimicrobial resistance, which can put patients at risk. It presented these points as reasons for the proposed rule, not as findings about a named manufacturer or drug.
The draft invites objections and suggestions within 30 days after copies of the Gazette rules are made available to the public. The ministry’s announcement did not say when public availability began, so the comment period’s start date and deadline are unverified. The proposal has not been finalized, and no implementation date was announced.
In a separate proposal, the ministry would create distinct application and license forms for wholesalers handling bulk drugs, including active and inactive substances. It said current wholesale licenses cover both bulk drugs and formulations. The ministry announced that proposal separately.



